Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors
BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors
BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors
Submitted by
admin
on October 22, 2018 - 10:43am
Source:
CP Wire
News Tags:
BeiGene
pamiparib
solid tumors
Headline:
BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors
snippet:
Pamiparib is currently in Phase 3 trials globally and in China as a monotherapy
Of 23 patients with solid tumors, Ten had a best response of stable disease; four patients had a best response of disease progression
Do Not Allow Advertisers to Use My Personal information
